|Condition:||Diabetes Mellitus Type 2|
|Keywords:||GLP-1 mimetics, Glucagon-like peptide-1 receptor agonist, Blood Glucose lowering drugs, Type II|
Please select a BNF chapter code to go to the formulary.
060102 - Antidiabetic Drugs
|Date||Committee Name||Narrative||Traffic Light Status Traffic Light Status|
|07 February 2018||Prescribing Clinical Network||
THE PREFERRED GLP-1 RECEPTOR AGONIST:
NICE advises selecting the GLP-1 receptor agonist based on the lowest acquisition cost, where all other factors are equal.
Treatment should be reviewed at 6 months. If there is no beneficial metabolic response (defined in NICE guidance), then stop treatment, and consider alternative treatment (usually insulin initiation) in line with NICE guidance
|Type:||Document (click to view)||Review Date|
|Guidelines (Local)||Diabetes Type 2 -Treatment Guidelines - February 2018||February 2021|
|Patient resource||GLP-1 patient agreement form - February 2018||February 2021|
|Information||Antidiabetic treatments comparison- PrescQIPP resource - February 2018||February 2021|
|Information||Hypoglycaemic agents -Preferred choices - February 2018||February 2021|
|Information||Blood glucose control - Treatment algorithm - February 2018||February 2021|
No Supplementary Documents returned.